CALGARY, Aug. 6, 2015 /PRNewswire/ - Oncolytics Biotech® Inc. (TSX:ONC, NASDAQ: ONCY) (“Oncolytics” or the “Company”) today announced its financial results and operational highlights for the second quarter ended June 30, 2015.
“Subsequent to quarter end we announced compelling overall, one- and two-year survival data from the REO 017 study in patients with advanced pancreatic cancer treated with gemcitabine and REOLYSIN®,” said Dr. Brad Thompson, President and CEO of Oncolytics. “During the quarter we also added to our growing body of evidence that REOLYSIN® contributes to the upregulation of PD-1 and PD-L1 and so may play a role in immunotherapeutic treatment of cancer.”
To read full press release, please click here.
Help employers find you! Check out all the jobs and post your resume.
